ERG26 Antibody

What is ERG and what is its significance in prostate cancer research?

ERG is a member of the ETS family of transcription factors, specifically the ETS-related gene (ERG). In prostate cancer research, ERG has gained significant attention due to gene fusions between androgen-regulated genes (most commonly TMPRSS2) and ERG, which occur in approximately 50% of prostate cancers . These gene fusions lead to ERG protein overexpression, which can be detected using specific antibodies. Research has shown that ERG silencing leads to cell cycle arrest in prostate cancer cells, and lowering ERG protein expression reduces the proliferation and migration of prostate cancer cells, suggesting that ERG proteins play an important role in prostate cancer pathogenesis .

What are the fundamental applications of ERG antibodies in experimental settings?

ERG antibodies are primarily used in several key applications:

• Immunohistochemistry (IHC) on formalin-fixed paraffin-embedded tissues, particularly for prostate cancer diagnosis

• Western blotting for protein expression analysis

• Immunofluorescence for localization studies

• ELISA for quantitative detection

In diagnostic pathology, ERG antibodies have proven particularly valuable for evaluating needle biopsies, including diagnostically challenging cases where traditional markers may be insufficient . The ability to detect nuclear expression of ERG with high specificity makes these antibodies particularly useful for identifying ERG-rearranged prostate cancer.

How do researchers validate ERG antibody specificity for experimental use?

Validation of ERG antibody specificity typically involves multiple complementary approaches:

• Correlation with FISH (fluorescence in situ hybridization) detection of ERG gene rearrangements. Studies have demonstrated 95.7% sensitivity and 96.5% specificity of the ERG monoclonal antibody (clone EPR3864) compared to FISH for detecting ERG rearrangements .

• Testing on tissue microarrays containing known positive and negative controls. For instance, Park et al. validated ERG antibody specificity using tissue microarrays containing 207 cores of prostate cancer from prostatectomy specimens .

• Evaluation on benign prostate tissue, which should show minimal to no staining. Studies have demonstrated that ERG staining is present in only about 1% of benign prostate cores .

• Western blot analysis to confirm the antibody recognizes a protein of the expected molecular weight (approximately 54.6 kilodaltons) .

What immunohistochemical protocols yield optimal ERG staining in prostate tissues?

Based on research protocols, the optimal immunohistochemical method for ERG antibody staining involves:

• Tissue fixation in 10% neutral buffered formalin for 24 hours at room temperature

• Sectioning paraffin-embedded tissues at 4 μm thickness

• Dewaxing and antigen retrieval using Tris-EDTA buffer (pH 9.0) for 20 minutes in microwave, followed by cooling to room temperature for 20 minutes

• Blocking endogenous peroxidase with 0.3% hydrogen peroxide in phosphate-buffered saline at room temperature for 15 minutes

• Incubation with primary ERG antibody (typically diluted at 1:200) for 60 minutes at room temperature

• Incubation with secondary antibody for 45 minutes at room temperature

• Development with diaminobenzidine and counterstaining with hematoxylin

This protocol has been demonstrated to produce consistent nuclear staining in ERG-positive samples with minimal background.

How should researchers interpret variable ERG staining patterns in prostate cancer specimens?

Interpretation of ERG staining patterns requires careful consideration of:

What are the methodological differences between ERG antibody clones for research applications?

Several ERG antibody clones have been used in research, with important methodological differences:

• Clone EPR3864 (anti-C terminus): This is one of the most extensively validated clones, demonstrating 95.7% sensitivity and 96.5% specificity compared to FISH for ERG rearrangements . This clone targets the C-terminus of ERG, which is retained in all known ERG gene fusions.

• Clone C3: Another C-terminal targeting antibody used in immunohistochemistry applications with demonstrated efficacy in FFPE tissues .

• Polyclonal antibodies: Generally show lower specificity than monoclonal options and may cross-react with other ETS family members.

When selecting an antibody clone, researchers should consider:

• The specific epitope recognized (most validated clones target the C-terminus)

• Validation data comparing the antibody to FISH results

• Potential cross-reactivity with other ETS family members (such as FLI1)

• The intended application (IHC-P, Western blot, IF, etc.)

How can ERG antibodies be integrated into multiplex immunostaining systems for complex tumor microenvironment studies?

For advanced multiplex immunostaining incorporating ERG antibodies:

• Sequential multiplex immunostaining: Researchers can use ERG antibodies in combination with other markers using sequential staining protocols. For example, dual staining with p63 (a basal cell marker) and ERG has been used to evaluate challenging prostate biopsies .

• Spectral unmixing approaches: Using different chromogens or fluorophores, ERG can be combined with markers of tumor microenvironment components (immune cells, stromal cells, etc.) to study their spatial relationships.

• Automated multiplex platforms: Several commercial platforms now support multiplex IHC, allowing for the simultaneous detection of ERG along with other relevant markers.

• Data analysis considerations: When analyzing multiplex data, researchers should employ appropriate image analysis software capable of cell-level colocalization analysis and quantification of staining intensities.

The advantage of including ERG in multiplex panels is its high specificity for prostate cancer cells (>99% specific for prostate cancer or HGPIN adjacent to ERG-rearranged prostate cancer) , making it an excellent marker to distinguish tumor cells from other components in complex tissue microenvironments.

What is the significance of discordant ERG expression patterns between primary tumors and metastatic lesions?

Discordant ERG expression patterns between primary and metastatic prostate cancer lesions provide important insights into tumor evolution:

• Clonal evolution: Differences in ERG expression may reflect clonal selection during metastatic progression, with either ERG-positive or ERG-negative clones having metastatic advantages in specific microenvironments.

• Molecular subtypes: ERG expression discordance supports the concept of distinct molecular subtypes of prostate cancer with different biological behaviors. Understanding these subtypes may help predict disease progression and treatment response.

• Methodological considerations for researchers:

  • Paired analysis of primary and metastatic sites should be performed when possible

  • Heterogeneity within primary tumors should be thoroughly assessed before comparing to metastases

  • Multiple metastatic sites should be evaluated when available to determine consistency of ERG status

How can researchers utilize ERG antibodies to study the functional consequences of different ERG fusion variants?

To study functional consequences of different ERG fusion variants:

• Comparative IHC studies: Researchers can use ERG antibodies in conjunction with RNA-based methods to correlate protein expression levels with specific fusion variants.

• Functional assays: After identifying specific variants through genomic methods, ERG antibodies can be used in functional studies to:

  • Assess nuclear localization patterns

  • Evaluate interactions with chromatin through ChIP assays

  • Investigate protein-protein interactions through co-immunoprecipitation

  • Monitor changes in ERG levels following experimental interventions

• In vitro models: Using cell lines with different ERG fusion variants, researchers can employ ERG antibodies to:

  • Validate knockdown or overexpression models

  • Monitor protein levels during drug treatments

  • Correlate ERG expression with phenotypic changes

• Tissue-based investigations: By combining ERG IHC with detailed genetic analysis of fusion breakpoints, researchers can explore associations between specific variants and clinical outcomes.

How does ERG antibody immunohistochemistry compare with other molecular markers in diagnosing challenging prostate biopsies?

ERG antibody IHC offers several advantages compared to other molecular markers:

• Specificity comparison: ERG staining is more prostate cancer-specific than alpha-methylacyl-CoA racemase (AMACR), a commonly used marker . The data shows ERG is expressed in only 1.2% of benign cores, versus higher false-positive rates with AMACR.

• Complementary value: In diagnostically challenging cases requiring IHC:

  • ERG positivity in 28.2% of prostate cancer cores

  • ERG positivity in only 2.9% of benign cores after standard diagnostic workup

• Application in atypical foci: ERG expression in atypical focus supports a diagnosis of cancer if HGPIN can be excluded .

• Value in minute cancerous foci: ERG staining is effective even in minute cancerous foci (≤5% core involvement), with 37% (22/60) of such cores showing ERG expression . This makes it particularly valuable for challenging biopsies with minimal tumor involvement.

What is the current evidence supporting the prognostic significance of ERG expression in prostate cancer?

Current evidence on the prognostic significance of ERG expression includes:

• Biochemical recurrence: Significant difference in biochemical recurrence (p=0.017) between patients with positive and negative ERG expression has been observed. Patients with positive ERG expression had significantly worse biochemical failure-free survival curves compared to those with negative ERG expression (p=0.0038) .

• Multivariate analysis: In multivariate Cox regression analysis, positive ERG expression was found to be an independent prognostic factor in patients with prostate cancer who underwent radical prostatectomy (hazard ratio, 4.08; 95% confidence interval, 2.03-8.17; p=0.000074) .

• Geographic and ethnic variations: Research indicates differences in ERG positivity rates between populations:

  • Approximately 16.6% in Asian populations

  • Approximately 50% in European and American populations

These findings suggest that ERG expression assessment by IHC may have value for risk stratification in patients with prostate cancer, potentially identifying those at higher risk for biochemical recurrence following radical prostatectomy.

How should researchers design longitudinal studies to evaluate the stability of ERG expression during prostate cancer progression and treatment?

For robust longitudinal studies evaluating ERG expression stability:

• Study design considerations:

  • Prospective cohort design with serial sampling

  • Inclusion of treatment-naïve and post-treatment specimens

  • Sampling of the same tumor regions when possible

  • Inclusion of multiple tumor foci to account for heterogeneity

• Standardized assessment protocols:

  • Use of the same antibody clone throughout the study period

  • Consistent IHC protocols with appropriate controls

  • Digital image analysis to quantify staining intensity objectively

  • Blinded pathological assessment

• Integration with other data sources:

  • Correlation with PSA kinetics

  • Integration with treatment response metrics

  • Association with development of castration resistance

  • Comparison with circulating tumor DNA analysis for TMPRSS2-ERG fusion

• Advanced analytical approaches:

  • Time-to-event analysis for ERG status changes

  • Mixed effects models to account for repeated measures

  • Propensity score matching to adjust for treatment effects

  • Multistate modeling to track transitions in ERG status

A well-designed longitudinal study should account for potential confounding factors such as tumor heterogeneity, treatment effects, and technical variability in immunohistochemistry.

What are the most effective methods for correlating ERG antibody immunohistochemistry with genomic detection of TMPRSS2-ERG fusion?

To effectively correlate ERG IHC with genomic detection of TMPRSS2-ERG fusion:

• Sequential tissue analysis:

  • Perform IHC on one section

  • Extract nucleic acids from adjacent sections for genomic analysis

  • Use laser capture microdissection if necessary to ensure sampling of the same cell populations

• Genomic detection methods:

  • FISH remains the gold standard for detecting ERG rearrangements, with antibody testing showing 95.7% sensitivity and 96.5% specificity compared to FISH

  • RT-PCR targeting specific fusion breakpoints

  • RNA-seq for comprehensive fusion detection

  • Targeted DNA sequencing panels including TMPRSS2 and ERG

• Data integration approaches:

  • Cell-by-cell mapping of genomic and protein expression data

  • Correlation analysis of signal intensities

  • Discordance analysis to identify post-transcriptional regulatory mechanisms

• Validation in model systems:

  • Use of well-characterized cell lines with known fusion status

  • Creation of isogenic cell models with and without the fusion

  • Xenograft models to validate in vivo correlation

What quality control measures should researchers implement when using ERG antibodies in multi-center clinical studies?

For multi-center clinical studies using ERG antibodies, the following quality control measures are essential:

• Pre-analytical standardization:

  • Standardized tissue procurement and fixation protocols

  • Consistent tissue processing methods

  • Centralized antibody procurement and lot testing

  • Defined storage conditions for specimens and reagents

• Analytical standardization:

  • Centralized protocol development and distribution

  • Use of automated staining platforms when possible

  • Inclusion of standardized positive and negative controls with each batch

  • Regular calibration of equipment

• Interpretation standardization:

  • Development of a scoring atlas with representative images

  • Training sessions for participating pathologists

  • Regular proficiency testing with unknown samples

  • Digital pathology integration for centralized review

• Inter-laboratory validation:

  • Exchange of samples between centers for cross-validation

  • Statistical assessment of inter-observer and inter-center variability

  • Hierarchical analysis to identify center-specific effects

  • Adjustment for center effects in statistical analyses

• External quality assessment:

  • Participation in external quality assurance programs

  • Independent validation of a subset of samples at a reference laboratory

  • Regular protocol review and update based on quality metrics

  • Documentation of antibody lot changes and validation

Implementing these measures ensures reliable and comparable results across different research centers, enhancing the validity of multicenter studies on ERG expression in prostate cancer.